STOCK TITAN

If You Invested in Enfusion, Inc. (ENFN)

Services-prepackaged Software · NYSE
See the ENFN overview
ENFN has not traded since Apr 17, 2025. Its last close was $10.76, so every figure on this page ends there and the 1, 5 and 10 year results count back from that close.
$1,000 invested 1 Year Before Its Last Close
$1,157
+15.7% price return 15.7% CAGR
+15.7% with dividends reinvested
Bought on Apr 17, 2024 at $9.30 split-adjusted
$1,000 invested 5 Years Before Its Last Close
N/A
Our prices start Oct 21, 2021
$1,000 invested 10 Years Before Its Last Close
N/A
Our prices start Oct 21, 2021

What $1,000 or $10,000 in ENFN Was Worth at Its Last Close

Real historical value by amount invested and how long before the last close
If you invested 1 year before 5 years before 10 years before Since Oct 21, 2021
$1,000 $1,157 +16% — — $543 -46%
$10,000 $11,570 +16% — — $5,432 -46%

Based on real historical closing prices adjusted for stock splits, without dividends, through 2025-04-17. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.

Custom Calculation

Choose your own date and amount for ENFN

$1,000 Investment Over Time

ENFN vs S&P 500

Year-by-Year Returns

ENFN annual performance
Year Start Price End Price Annual Return Cumulative
2021Oct 21 to Dec 31 $19.81 $20.94 +5.7% +5.7%
2022 $20.94 $9.67 -53.8% -51.2%
2023 $9.67 $9.70 +0.3% -51.0%
2024 $9.70 $10.30 +6.2% -48.0%
2025Dec 31, 2024 to Apr 17 $10.30 $10.76 +4.5% -45.7%

About Enfusion, Inc.

NYSE

Enfusion, Inc. (NYSE: ENFN) is a software company focused on the financial services industry. According to available information, Enfusion provides software-as-a-service (SaaS) solutions designed for investment managers, hedge funds, and asset managers. The company is associated with the software publishers industry within the information sector.

Enfusion is described as an investment management SaaS platform that removes traditional information boundaries by uniting front-, middle-, and back-office teams on one system. Through its software, analytics, and middle/back-office managed services, Enfusion aims to support real-time, data-driven workflows and collaboration for institutional investors. Its platform is cited as providing real-time portfolio and order management, IBOR, risk analytics, and reporting in one system, with an emphasis on eliminating batch processing, manual reconciliation, and data duplication.

Available descriptions note that Enfusion partners with hundreds of investment managers and operates from multiple global offices across several continents. The company has been referenced as serving hedge funds and asset managers and as working with investment managers across different strategies and asset classes. Its solutions are positioned as a technology foundation for modern investment operations, with a focus on front-office capabilities integrated with operational and reporting functions.

In a corporate development, Enfusion is identified in news reports as “a Clearwater Analytics company” and as being acquired by Clearwater Analytics Holdings, Inc. (NYSE: CWAN) in a transaction valued at approximately $1.5 billion. A press release dated April 21, 2025, states that Clearwater completed its acquisition of Enfusion, and that Enfusion’s technology is being combined with Clearwater’s middle- and back-office platform to form a unified, cloud-native front-to-back investment management offering. Historical news also details the merger agreement announced on January 13, 2025, under which Clearwater agreed to acquire Enfusion for a mix of cash and stock.

Prior to the acquisition, Enfusion reported financial results as an independent public company. For example, Enfusion announced financial results for the fourth quarter and full year ended December 31, 2024, including revenues, margins, and other metrics. These disclosures characterize Enfusion as a recurring-revenue SaaS business serving investment managers, with platform subscriptions and managed services as key revenue categories. The company also tracks metrics such as Annual Recurring Revenue (ARR), Average Contract Value (ACV), and Net Dollar Retention Rate as indicators of its business performance.

Earlier descriptions from market data sources further characterize Enfusion as a cloud-based portfolio management and risk system provider. It has been described as headquartered in Chicago, Illinois, with a branch office in New York, New York, and wholly owned subsidiaries in London and Hong Kong. Clients are described as relying on real-time performance, risk calculations, and accounting for sophisticated financial products, and the company has been noted as serving hedge funds with substantial assets under management. These details provide historical context on Enfusion’s geographic footprint and client base.

Following the completion of the Clearwater transaction, Enfusion’s ticker symbol ENFN represents the historical listing of the company as a standalone issuer. Current references in news releases describe Enfusion as operating within Clearwater as part of a broader front-to-back investment management platform. Investors researching ENFN can use this page to understand the company’s historical role as a SaaS provider to investment managers and its subsequent integration into Clearwater’s business.

Business Focus

Based on company and transaction disclosures, Enfusion’s core focus includes:

  • Investment management SaaS platform that unites front-, middle-, and back-office teams on one system.
  • Front-office technology foundation for hedge funds and asset managers, including portfolio and order management and IBOR.
  • Risk analytics and reporting delivered in real time to support operational workflows and portfolio oversight.
  • Middle/back-office managed services associated with its software platform.

Corporate Status and Relationship with Clearwater Analytics

News releases state that Clearwater Analytics and Enfusion entered into a definitive merger agreement for Clearwater to acquire Enfusion, with the transaction anticipated to close in the second quarter of 2025. A later release dated April 21, 2025, reports the successful completion of Clearwater’s acquisition of Enfusion in a deal valued at approximately $1.5 billion and refers to Enfusion as “a Clearwater Analytics company.” These statements indicate that Enfusion transitioned from an independent public company to part of Clearwater’s consolidated operations.

For users examining ENFN as a historical ticker, this context is important: ENFN relates to Enfusion’s period as a separately listed entity on the New York Stock Exchange prior to and through its acquisition by Clearwater. Subsequent operations and branding are described in public communications as part of Clearwater’s platform.

Last Close
$10.76
View full ENFN overview

Frequently Asked Questions

Enfusion, Inc. investment returns

How much was $1,000 invested in Enfusion, Inc. worth at its last close?

If you invested $1,000 in Enfusion, Inc. (ENFN) 1 year before its last close, on 2024-04-17, your investment was worth $1,157 on 2025-04-17, a +15.7% price return without dividends, growing at a compounded rate of 15.7% per year (CAGR).

Has Enfusion, Inc. outperformed the S&P 500?

Comparison data requires at least 10 years of trading history. Use the calculator above to compare ENFN performance over available time periods.

What is Enfusion, Inc.'s average annual return?

The compound annual growth rate (CAGR) of ENFN’s share price over the 1 year to Apr 17, 2025 is 15.7%, without dividends. Individual years vary a great deal, and ENFN’s best recent full year was 2024 (+6.2%) while the worst was 2022 (-53.8%).

For informational and educational purposes only, not investment advice.